Revenue growth

07/11/19 11:03 augustine - BTG PLC
For the twelve months ended 31 March, 2019, the annual report reflects a 12% total revenue growth to US$914.1 million against US$822.8 million reported in the prior twelve months. Product sales were US$634.7 million, up 14% from the prior twelve months (2018: US$561.2 million), primarily driven by a 16% CER increase in Oncology and Vascular sales. Pharmaceuticals sales grew 13% at CER. 
The position of account Deferred Long Term Asset Charges has moved above No account name found.
The position of account Property Plant And Equipment has moved above No account name found.
The position of account Other Assets has moved above No account name found.
The amount value of account Other Assets for balance date 31/03/14 changed from 1,700,000 GBP to 8,900,000 GBP.

Cash flow